Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Experience of the use of hydroxychloroquine on patients with COVID-19: A perspective on viral load and cytokine kinetics

Wang-Da Liu, Sui-Yuan Chang, Ting-Yuan Lan, Yen-Chun Lin, Jui-Hung Kao, Chun-Hua Liao, Ming-Jui Tsai, Po-Hsien Kuo, Yu-Shan Huang, Jann-Tay Wang, Wang-Huei Sheng, Song-Chou Hsieh, Bor-Luen Chiang, Yee-Chun Chen, Shan-Chwen Chang

Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan
Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan
Department of Pediatrics, National Taiwan University Children's Hospital, Taipei, Taiwan
Center of Infection Control, National Taiwan University Hospital, Taipei, Taiwan
Department of Medical Education, National Taiwan University Hospital, Taipei, Taiwan
Department of Internal Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan
Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan

Received 26 June 2020; received in revised form 14 August 2020; accepted 19 August 2020

Until now, there are no approved treatment against COVID-19. Hydroxychloroquine (HCQ) was hypothesized to be active against SARS-CoV2 via antiviral and anti-inflammatory effect; however, HCQ for COVID-19 in clinical use remained debating. In this preliminary report, we presented six patients with mild to moderate COVID-19. They were treated with HCQ for 14 days from the day of COVID-19 diagnosis. Serial viral load from respiratory specimens were performed every other day. Cytokine profile was checked before HCQ initiation and on the 14th day of HCQ treatment. All patients receiving HCQ completed 14-day course without complication. Among the six patients, the mean duration from symptom onset to last detectable viral

KEYWORDS
SARS-CoV-2; Interleukin; Coronavirus; Interferon; Cytokine

* Corresponding author. Department of Internal Medicine, National Taiwan University Hospital, No. 7, Chung-Shan South Rd., Taipei, 10002, Taiwan. Fax: +886 2 23971412.
E-mail addresses: b95401043@ntu.edu.tw (W.-D. Liu), sychang@ntu.edu.tw (S.-Y. Chang), d20023579@gmail.com (T.-Y. Lan), b95401009@ntu.edu.tw (Y.-C. Lin), juhungkaotw@gmail.com (J.-H. Kao), shiva90345@gmail.com (C.-H. Liao), flophoenix@gmail.com (M.-J. Tsai), kphsien@gmail.com (P.-H. Kuo), b101091021@gmail.com (Y.-S. Huang), wang.jt1968@gmail.com (J.-T. Wang), whsheng@ntu.edu.tw (W.-H. Sheng), hsiehsc@ntu.edu.tw (S.-C. Hsieh), gcicmbor@ntu.edu.tw (B.-L. Chiang), yeechunchen@gmail.com (Y.-C. Chen), changsc@ntu.edu.tw (S.-C. Chang).

** These authors contributed equally to this paper.

https://doi.org/10.1016/j.jfma.2020.08.022
0929-6646/Copyright © 2020, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Coronavirus disease 2019 (COVID-19) has caused catastrophic pandemics since late 2019, with clinical features from asymptomatic infection to multiorgan failure owing to cytokine storm. Until now, there are no approved treatments against COVID-19, while many drugs have been hypothesized to be active via antiviral or anti-inflammatory effect. Hydroxychloroquine (HCQ) was theoretically to be actively against SARS-CoV-2 via interfering with the glycosylation of ACE2, blocking virus/cell fusion and inhibiting lysosomal activity by increasing intracellular pH level, and have anti-inflammatory effect by inhibiting the production and release of TNF and IL-6. Animal studies had demonstrated HCQ can efficiently inhibit SARS-CoV-2 infection in vitro, along with its anti-inflammatory function. However, a previous retrospective study revealed that treatment with hydroxychloroquine, azithromycin, or both was not associated with higher viral loads or cytokine data. Moreover, a previous retrospective study revealed that treatment with hydroxychloroquine, azithromycin, or both was not associated with significantly lower in-hospital mortality.

Between January 2020 and April 2020, there were 17 confirmed cases of COVID-19 hospitalized at National Taiwan University Hospital. They were confirmed through reverse transcription-polymerase chain reaction (RT-PCR) test of SARS-CoV-2 envelope (E), nucleocapsid (N), and RNA-dependent RNA polymerase (RdRp) gene. Six of them were prescribed with HCQ upon admission, with a loading dose of 400 mg twice daily for the first seven days, and followed by 200 mg twice daily for another seven days. Azithromycin was not given due to potential cardiac toxicity in the context of co-administration with HCQ. During hospitalization, blood tests for hemogram, C-reactive protein, ferritin were checked twice per week, including the period of HCQ treatment. Cytokine profile was checked before HCQ initiation and on the 14th day of HCQ treatment. Chest radiograph were arranged once per week. Sputum, nasal swab and throat swab specimens were collected for examinations of SARS-CoV-2 RT-PCR every other day. Plasmid DNA containing the SARS-CoV-2 targeted E gene, was used to construct the standard curve to estimate the SARS-CoV-2 viral load by real-time RT-PCR tests.

**Results**

The demographic features of the patients are presented in the Table (See Table 1). Most of them were young female. All patients had mild respiratory symptoms before admission. None of them had respiratory distress. Initially, no leukocytosis or elevated C-reactive protein level was noted. At presentation, only one patient (Case 1) had fever (38.3 °C) with chills, and her chest radiography revealed increasing infiltration over bilateral lung fields. The other five patients had normal chest X-ray image upon admission. Fever and airway symptoms of all six patients resolved within a week after admission. No new subjective discomfort, including nausea, abdominal pain, diarrhea or palpitation, was complained during HCQ therapy. All patients were discharged without complication after three consecutive sets of negative RT-PCR results from sputum, nasal swab and throat swab specimens.

Virology data from upper and lower airway specimens are presented in Fig. 1. Those with more serious symptoms and admitted in the early stage of clinical symptoms tend to have higher viral loads of sputum specimens (Case 1–3, >10^5 copies/mL), compared with those who were admitted in their late stage of infection (Case 4–6, <10^3 copies/mL). Of Case 1, 2 and 3, viral load from upper airway specimens showed a decrease of 2 logs or more within seven days after starting HCQ treatment. Among the six patients, the mean duration from symptom onset to last detectable viral load was 34 ± 12 days.

All six patients were found to have extremely low titers of interferon-gamma (IFN-γ) upon admission and on the 14th day of HCQ therapy. Most of the cytokines we checked upon admission were in low titers or undetectable; except for Case 5, who was admitted 14 days after initial symptom onset and was found to have a high IL-17 level. Three of the six patients were found to have mildly elevated IL-17 level after 14-day HCQ treatment. Mild elevated IL-6 level was observed in four of six patients upon their admission, and all patients had low level or undetectable IL-6 after HCQ treatment.

**Discussion**

Until now, the efficacy of HCQ for treating COVID-19 remained controversial. A retrospective study by
| Table 1 | Demographics, clinical features at admission, treatment, and outcomes of the patients. |
|---------|-----------------------------------------------------------------------------------|
|         | Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | Case 6 |
| **Demographics** |        |        |        |        |        |        |
| Age (years) | 26     | 58     | 37     | 22     | 29     | 23     |
| Gender | Female | Male | Female | Female | Female | Female |
| Comorbidities | Chronic urticaria | Hypertension | Hypertension | Hypertension | Allergic rhinitis | Allergic rhinitis |
| **Clinical features on admission** |        |        |        |        |        |        |
| Duration of symptoms before admission (days) | 3 | 8 | 9 | 3 | 14 | 30 |
| Clinical features | Fever, chills, sore throat, malaise | sore throat, dry cough, cervical lymphadenopathy | dry cough, malaise, rhinorrhea, dyspnea | rhinorrhea, sore throat, malaise, productive cough, nausea, vomiting, diarrhea | loss of smell and taste, rhinorrhea |
| **Diagnosis** | Pneumonia | URI | URI | URI | URI | URI |
| **Symptoms and vital signs** |        |        |        |        |        |        |
| Temperature (°C) | 38.3 | 36.3 | 37 | 36.3 | 36.4 | 36 |
| Heart rate (/min) | 86 | 66 | 94 | 78 | 78 | 84 |
| Respiratory rate (/min) | 20 | 18 | 15 | 20 | 20 | 20 |
| Blood pressure (mmHg) | 120/78 | 149/92 | 133/72 | 123/68 | 104/80 | 122/79 |
| O2 saturation in ambient air | 100 | 99 | 98 | 100 | 100 | 100 |
| **Laboratory results** |        |        |        |        |        |        |
| Hb (g/dL) | 10.9 | 15 | 12.5 | 14 | 12.9 | 12 |
| WBC (cells/μL) | 5230 | 3960 | 6150 | 2500 | 7950 | 6910 |
| Lym (%) | 21.4 | 39.9 | 12 | 39.6 | 28.6 | 24.9 |
| Platelet (K/μL) | 310 | 160 | 214 | 225 | 282 | 288 |
| CRP (mg/dL) | 0.17 | 0.11 | 0.15 | 0.02 | 0.17 | 0.02 |
| ALT (U/L) | 7 | 33 | 17 | 13 | 8 | 8 |
| LDH (U/L) | 151 | 169 | 145 | 190 | 134 | 131 |
| CK (U/L) | 31 | 162 | 45 | 47 | 29 | 58 |
| Ferritin (ng/mL) | 5.85 | 459.44 | 42.58 | 72.74 | 138.11 | 3.76 |
| Viral load from throat swab specimens (copies/mL) | 12,491 | 1,308,309 | 2,843,264 | 2,843,264 | 2,843,264 | 2,843,264 |
| Days of SARS-CoV-2 IgG detection after symptom onset (days) | 17 | 14 | 28 | NA | 14<sup>a</sup> | 30<sup>a</sup> |
| **Cytokine profile (pg/mL)** |        |        |        |        |        |        |
| IL-17 | Day 0 | 0 | 0 | 0 | 0 | 114.74 | 0 |
| Day 14 | 5.83 | 32.39 | 0.02 | 15.32 | 1.46 |
| IFN-γ | Day 0 | 0 | 0 | 0 | 0 | 0 |
| Day 14 | 0 | 0 | 0.21 | 0 | 0.06 |
| TNF | Day 0 | 0 | 0 | 0 | 0.14 | 0 |
| Day 14 | 0 | 0 | 0 | 0 | 0 |
| IL-10 | Day 0 | 0.82 | 0.04 | 0.61 | 0 | 0.65 | 0 |
| Day 14 | 0.39 | 0.78 | 0.49 | 0.28 | 0.36 | 0.45 |
| IL-6 | Day 0 | 2.84 | 2.84 | 0 | 1.6 | 5.2 | 0 |
| Day 14 | 0 | 2.43 | 0.24 | 0.29 | 0 | 1.89 |
| IL-4 | Day 0 | 0.16 | 0 | 0 | 0 | 0 |
| Day 14 | 0 | 0.13 | 0 | 2.24 | 0 | 0 |
| IL-2 | Day 0 | 0 | 0 | 0.27 | 0.27 | 0 |
| Day 14 | 0 | 0.31 | 0 | 0.51 | 0 | 0 |
| **Treatment and outcomes** |        |        |        |        |        |        |
| Duration from symptom onset to last detectable viral load (days) | 47 | 38 | 33 | 16 | 25 | 46 |
| Length of hospital stay (days) | 52 | 35 | 28 | 22 | 20 | 24 |
| Outcomes | Survived | Survived | Survived | Survived | Survived | Survived |

**Abbreviation:** URI, upper respiratory infection; Hb, hemoglobulin; Lym, lymphocyte; CRP, C-Reactive protein; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; CK, creatine kinase; IL, interleukin; IFN-γ, interferon gamma; TNF, tumor necrosis factor.  
<sup>a</sup> SARS-CoV-2 specific IgG could be detected from the serum sampled upon admission.
Rosenberg ES et al. revealed that treatment with hydroxychloroquine, azithromycin, or both was not associated with lower in-hospital mortality among COVID-19 patients. An open-label, randomized controlled trial of 150 patients with mild to moderate disease, also demonstrated that the use of HCQ did not show significant difference in negative conversion of SARS-CoV-2 by 28 days compared with standard of care.5 Besides, a randomized trial by Boulware et al. also revealed HCQ did not prevent illness compatible with Covid-19 or confirmed infection when used as post-exposure prophylaxis within four days after exposure.6 However, whether HCQ is able to prevent SARS-CoV-2 infection as pre-exposure prophylaxis remained uncertain.

Our study echoes the finding that the administration of HCQ is not associated with acceleration of virus clearance. Among our patients, three with initial higher viral load showed a decrease of 2 logs or more in their viral loads within seven days after starting HCQ treatment, which was similar to previous reports of patients without any antiviral or antiinflammation medications.7,8

Among our cases, three of them had elevation of IL-17 level, which was considered as an essential role in several inflammatory respiratory diseases. The reported cases demonstrated that the elevation of IL-17 was observed even in patients with only mild disease of COVID-19. Casillo et al. thus hypothesized IL-17 as a potential therapeutic target.9 Previous reports revealed that HCQ inhibits the differentiation of Th-17 cells and decreased the release of IL-17 from the experience of treating systemic lupus erythematosus.10 Early administration of HCQ among our patients might inhibit the cytokine release and thus prevent hyperinflammation events, which potentially leads to deteriorating clinical condition. Nevertheless, the impact of HCQ on cytokine kinetics in COVID-19 patients still needs further studies.

In addition, low level of interferon-gamma was noted in our patients of different stages of infection, which implied atypical immune response against SARS-CoV-2 infection. Previous reports revealed that SARS-CoV-2 replicates stealthily in host cells without detectably triggering type I and III interferon, leading to high viral loads and impaired control for inflammation.11 Our study demonstrated the immune response was impaired not only found in type I and III interferon, but also found in type II interferon.

Our case series demonstrated our experience of HCQ use in patients with mild to moderate COVID-19. Prolonged virus shedding is still observed regardless of HCQ. The impact of HCQ on cytokine kinetics remained unclear; however, IL-17 could be an inflammatory marker for disease status monitor and a potential therapeutic target. The impact on clinical course, viral shedding and cytokine kinetics still needs further investigation.

Fig. 1 Viral load kinetics from respiratory specimens of throat swab (A) and sputum (B).
COVID-19, hydroxychloroquine and viral load kinetics

Declaration of Competing Interest

none to declare.

Acknowledgments

This study is supported by National Taiwan University Hospital TOP DOWN Project (NO. 109-P13 and NO. 109-P14).

References

1. Tunesi S, Bourgarit A. Prescribing COVID-19 treatments: what we should never forget [published online ahead of print, 2020 May 13] J Infect 2020;81(2):e85. https://doi.org/10.1016/j.jinf.2020.05.018.

2. Tripathy S, Dassarma B, Roy S, Chabalala H, Matsabisa MG. A review on possible modes of actions of Chloroquine/Hydroxychloroquine: repurposing against SAR-COV-2 (COVID 19) pandemic [published online ahead of print, 2020 May 22]. Int J Antimicrob Agents 2020;106028.

3. Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020;6:16.

4. Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state. JAMA. Published online May 11, 2020. doi:10.1001/jama.2020.8630.

5. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ 2020;369:m1849.

6. Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med 2020. https://doi.org/10.1056/NEJMoa2016638 [published online ahead of print, 2020 Jun 3].

7. Liu WD, Chang SY, Wang JT, Tsai MJ, Hung CC, Hsu CL, et al. Prolonged virus shedding even after seroconversion in a patient with COVID-19 [published online ahead of print, 2020 Apr 10] J Infect 2020;81(2):318–56. https://doi.org/10.1016/j.jinf.2020.03.063.

8. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-19. Nature 2020;581(7809):465–9.

9. Casillo GM, Mansour AA, Raucci F, Saviano A, Mascolo N, Iqbal AJ, et al. Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome? Pharmacol Res 2020;156:104791.

10. Yang J, Yang X, Yang J, Li M, Li M. Hydroxychloroquine inhibits the differentiation of Th17 cells in systemic lupus erythematosus. J Rheumatol 2018;45(6):818–26.

11. Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Møller R, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 2020;181(5):1036–45. e9.